mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. by Kondo, S. et al.
Britsh Journal of Cancer (1996) 74, 1263-1268
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 $
mdm2 gene mediates the expression of mdrl gene and P-glycoprotein in a
human glioblastoma cell line
S Kondol, Y Kondo2, H Hara3, R Kaakajil, JW Peterson2, T Morimura4, J Takeuchi4 and
GH Barnett'
'Department ofNeurosurgery/S80, Brain Tumor Center/Cancer Center and 2Department ofNeurosciences/NC3, The Cleveland
Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA; 3Department ofClinical Research Center and 4Department of
Neurosurgery, National Utano Hospital, Ukyo-ku, Kyoto 616, Japan.
Summary The overexpression of the multidrug resistance (mdrl) gene and its product, P-glycoprotein (P-gp),
is thought to limit the successful chemotherapy ofhuman tumours. The mechanism by which mdrl gene and P-
gp are overexpressed in human tumours, however, is not yet clear. In this report, we show that the mdm2
(murine double minute 2) gene induced the expression of the mdrl gene and P-gp in human glioblastoma U87-
MG cells, which did not express the MDM2 protein or P-gp. The mdm2 gene, in addition, conferred the
resistance of U87-MG cells to the apoptotic cell death induced by etoposide (VP-16) or doxorubicin.
Furthermore, treatment with mdm2 antisense oligonucleotides inhibited the expression of P-gp in MDM2-
expressing U87-MG cells. These findings suggest that the mdm2 gene may play an important role in the
development of MDR phenotype in human tumours.
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The development of the multidrug resistance (MDR)
phenotype in human tumours is thought to be a major
obstacle to successful chemotherapy. The MDR phenotype is
associated with increased expression of the mdrl gene
(Roninson et al., 1984; Gros et al., 1986; Ueda et al.,
1987). This gene codes for a high molecular weight membrane
glycoprotein of 170 kDa, P-gp (Juliano and Ling, 1976).
Expression of the mdrl gene and P-gp occurs commonly in
tumours derived from normal tissues such as colon, liver,
kidney, pancreas and adrenal gland that express the
multidrug transporter intrinsically (Fojo et al., 1987;
Thiebaut et al., 1987; Croop et al., 1989; Goldstein et al.,
1989). However, some tumours derived from non-mdrl-
expressing tissues, such as acute non-lymphocytic leukaemia
and neuroblastoma, express the mdrl gene and P-gp during
tumour progression (Ma et al., 1987; Chan et al., 1991). The
mechanism by which these cells overexpress mdrl and P-gp is
not fully understood.
Many genetic alterations occur within the cell during
tumour progression. The tumour-suppressor gene p53
mutations are the most common genetic alterations (Levine
et al., 1991; Vogelstein and Kinzler, 1992; Finlay, 1993;
Harris and Hollstein, 1993). Recent studies have demon-
strated that mutations of p53 affect mdrl gene promoter
activity (Chin et al., 1992; Zastawny et al., 1993). On the
other hand, the human homologue of the mdm2 gene coding
a p53-binding protein has recently been cloned (Oliner et al.,
1992). The product of this gene is shown to act as a negative
regulator of wild-type p53 protein and possesses oncogenic
activity like mutant p53 (Hinds et al., 1990; Fakharzadeh et
al., 1991; Momand et al., 1992; Barak et al., 1993).
Recently, we have obtained evidence that a human
glioblastoma cell line expressing P-gp also overexpresses
MDM2 protein (unpublished data). Therefore, we wished to
investigate whether the mdm2 gene is related to the expression
of the mdrl gene and P-gp in tumour cells. In this study, we
attempted to determine whether the mdm2 gene induces the
expression of the mdrl gene and P-gp in human glioblastoma
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U87-MG cells, which do not express MDM2 protein or P-gp,
and whether the mdm2 gene affects apoptosis in U87-MG
cells induced by VP-16 and doxorubicin.
Materials and methods
Tumour cells and mdm2 transfection
Human glioblastoma U87-MG cells (RIKEN Cell Bank,
Wako, Japan) were cultured in Dulbecco's modified Eagle
medium (DMEM) (Nissui, Tokyo, Japan) supplemented with
10% heat-inactivated fetal calf serum (FCS) (GIBCO, Grand
Island, NY, USA), 4 mM glutamine, 50 U/ml-'penicillin and
50 /ig/ml-' streptomycin. Stable mdm2-transfected cell clones
were generated as described previously (Kondo et al., 1995).
Tumour cells were seeded at a density of 6 x 105 per 100 mm
dish on day 1, and transfected on day 2 by the calcium
phosphate method (Mammalian Transfection kit, Stratagene,
La Jolla, CA, USA) with 10 jug of human mdm2 expression
vector pCMV-MDM2 (kindly supplied by Dr B Vogelstein)
(Oliner et al., 1992, 1993). On day 3, the cells were rinsed and
refed with fresh medium. On day 4, the cells were trypsinised
and seeded at 2 x 105 cells per 100 mm dish into G418
(300 Mgml-')-containing medium. After a one week period
of incubation at 37°C, six G418-resistant colonies were
cloned into medium with G418. The production of the
MDM2 protein in tumour cells was assessed by immunoblot-
ting using MAb to MDM2 (IF-2, Oncogene Science, NY,
USA).
RNA extraction and Northern blot analysis
Cytoplasmic RNA was extracted by the NP-40 lysis protocol
(Ginsberg et al., 1990). Northern blot analysis was performed
using Hybond N membrane (Amersham, Arlington Heights,
IL, USA) for transfer. The following cDNA probes were used
for hybridisation, human mdm2 (Oliner et al., 1992)
(nucleotides 579 to 949, kindly supplied by Dr B Vogel-
stein), human mdrl (Oncogene Science) and human GAPDH
(Oncogene Science). Each cDNA probe was labelled by ECL
random prime labelling system (Amersham). The blots were
hybridised to random-primed probes in a solution containing
5 x SSC, 0.1% sodium dodecyl sulphate (SDS), 5% dextran
sulphate and 100 ygml-' of denatured salmon sperm DNA
overnight at 60°C. Thereafter, the blots were washed first inmdm2 mediates the expression of mdrl and P-gp in glioma cells
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1 x SSC, 0.1% SDS for 15 min, then in 0.5 xSSC, 0.1% SDS
for a further 15 min at 60°C, and detected by ECL detection
system (Amersham), according to the manufacturer's
instructions.
Immunoblotting assay
Expression of MDM2 and P-gp in U87-MG cells was
confirmed by immunoblotting using MAb to MDM2 (IF-2)
and P-gp (Ab-1, Oncogene Science). Monolayers of U87-MG
cells were rinsed three times with ice-cold phosphate-buffered
saline (PBS), scraped off with a rubber policeman, pelleted at
8000 g for 5 min. For immunoblotting of MDM2 protein, cell
pellets were lysed in extraction buffer (10 mM Tris-HCl, pH 7,
140 mM sodium chloride, 3 mM magnesium chloride, 0.5%
NP-40, 2 mM phenylmethylsulphonyl fluoride (PMSF), 1%
aprotinin, 5 mM dithiothreitol) for 20 min on ice. The extracts
were cleared by centrifugation for 30 min at 10 000 g. For
immunoblotting of P-gp, cell pellets were lysed in buffer
(10 mM Tris-HCl, pH 7.4, 10 mM potassium chloride, 1.5 mM
magnesium chloride, 2 mM PMSF) for 10 min at 4°C, and
homogenised using a Branson sonicator (Waken, Kyoto,
Japan). The homogenate was subjected to centrifugation at
4000 g for 10 min to remove cell debris. The remaining
supernatant was subjected to ultracentrifugation at 100 000 g
for 1 h to yield a plasma membrane-enriched pellet. The final
pellet was resuspended in the lysis buffer. Equal amounts of
protein estimated by the BioRad protein assay (Richmond,
CA, USA) were subjected to electrophoresis on a 10% or 12%
polyacrylamide gel in SDS and thereafter subjected to
electrotransfer to the nitrocellulose membrane that was
saturated with PBS, pH 7.4, supplemented with 3% skimmed
milk powder and 0.1% Tween-20 (PMT) buffer for 2 h at room
temperature. The MDM2 or P-gp-specific MAb was incubated
at 4°C overnight with the membrane. The membrane was
washed in PMT buffer, incubated with a sheep anti-IgG-
horseradish peroxidase conjugate (1:1000 dilution) for 60 min
at room temperature. Then, the membrane was incubated with
the ECL reagents (Amersham) for 1 min and exposed to a
Hyperfilm-ECL for 5 to 6 min.
Anticancer drugs
VP-16 and doxorubicin were used in this study. VP-16 was
the generous gift of Nippon Kayaku Co. (Tokyo, Japan). It
was obtained in powder form, from which 10 mgml-l stock
solution was prepared in dimethyl sulphoxide. Doxorubicin
was the generous gift of Kyowa Hakko Kogyo (Tokyo). It
was also obtained in powder form, from which 1.0 mg ml-
stock solution was prepared in normal saline.
Cell viability
The cytotoxic effects of VP-16 and doxorubicin on U87-MG
and MDM2-U87-MG cells were evaluated by using a
modified MTT colorimetric assay (Yin et al., 1994). Briefly,
tumour cells were seeded at 104 cells per well (0.1 ml) in 96-
well flat-bottomed plates (Corning, NY, USA) and incubated
overnight at 37°C. Then, either VP-16 or doxorubicin was
added (10,l per well) to wells to achieve desired
concentrations between 0.01 and 20 ,ugml-'. Following a
72 h period of incubation at 37'C, 0.01 ml of MTT reagent
(Chemicon, Temecula, CA, USA) was added to each well.
Following another 4 h period of incubation at 37°C, 0.1 ml
isopropanol with 0.04 N hydrochloric acid was added to each
well to dissolve precipitates, and the absorbance was then
measured at 570 nm within 30 min of dissolution. The
statistical significance of findings was assessed using the
unpaired Student's t-test.
DNA fragmentation assay in agarose gel
DNA fragmentation assay was performed using methods
previously described (Yin et al., 1993). Briefly, harvested cells
(1 x 107) were centrifuged and washed twice with cold PBS.
The cell pellet was lysed in 1.0 ml of a buffer consisting of
10 mM Tris-HCl, 10 mM EDTA and 0.2% Triton X-100
(pH 7.5). After 10 min on ice, the lysate was centrifuged
(13 000 g) for 10 min at 4°C in an Eppendorf microtube.
Then, the supernatant (containing RNA and fragmented
DNA, but not intact chromatix¶) was extracted first with
phenol and then with phenol-chloroform-isoamyl alcohol
(25:24: 1). The aqueous phase was brought to 300 mM
sodium chloride and nucleic acids were precipitated with 2
volumes of ethanol. The pellet was rinsed with 70% ethanol,
air dried and then dissolved in 20 pl of 10 mM Tris-HCl-
1 mM EDTA (pH 7.5). Following digestion of RNA with
RNAase A (0.6 mg ml-', at 37°C for 30 min), the sample
was electrophoresed in a 2% agarose gel with Boyer's buffer
(50 mM Tris-HCl, 20 mm sodium acetate, 2 mM EDTA and
18 mM sodium chloride, pH 8.05). DNA was then visualised
with ethidium bromide staining.
In situ end labelling and Hoechst 33258 staining
To evaluate the structural integrity of the DNA in treated
individual tumour cells, free 3'-OH ends generated by
endonuclease cleavage of genomic DNA during apoptosis
were labelled with a commercial kit (ApopTag; Oncor,
Gaithersburg, MD, USA) based on a method similar to
that of Gavrieli et al. (1992), but which uses digoxigenin-11-
dUTP as label. To determine whether treated tumour cells
display an apoptotic morphology, moreover, tumour cells
were stained with Hoechst 33258 as described previously
(Kondo et al., 1995). Five hundred cells were counted and
scored for induction of apoptotic cells.
mdm2 antisense treatment
A 20-mer antisense oligonucleotide (5'-dGACATGTTGG-
TATTGCACAT-3'), complementary to a sequence beginning
at the position of the ATG initiation codon of mdm2 cDNA,
was synthesised and added to cultured tumour cells as
described previously (Kondo et al., 1995). The effects of
mdm2 antisense on P-gp expression and VP-16/doxorubicin-
induced cytotoxicity in MDM2-U87-MG cells were assayed
using immunoblotting and MTT assays. In order to control
for sequence-specific effects, mdm2 sense oligonucleotides (5'-
dCTGTACAACCATAACGTGTA-3') were prepared.
Results
Expression of mdrl and P-gp by mdm2
To determine whether the mdm2 gene induces the expression
of mdrl gene and P-gp in U87-MG cells, tumour cells were
transfected with a genomic human mdm2 gene. Parental U87-
MG cells expressed very low levels of mdm2 mRNA, and the
MDM2 protein was not detected (Figure la and b). In
addition, neither mdrl mRNA nor P-gp was detected in U87-
MG cells. Intriguingly, transfection of mdm2 gene not only
resulted in the overexpression of mdm2 gene and MDM2
protein, but also induced the expression of mdrl and P-gp in
U87-MG cells. The control vector pCMV, however, did not
induce them. These results show that the mdm2 gene induced
the expression of mdrl and P-gp in U87-MG cells.
Resistance to MDM2-U87-MG cells to VP-16 and doxorubicin
Since transfection ofmdm2 induced the expression ofmdrl and
P-gp in U87-MG cells, it was of interest to determine whether
MDM2-U87-MG cells acquired resistance to the anti-cancer
drugs, VP-16 and doxorubicin. As shown in Figure 2, MDM2-
U87-MG cells significantly acquired resistance to VP-16 and
doxorubicin when compared with parental U87-MG cells
(P<0.01 or P<0.01 respectively). The IC50 (MDM2-U87-MG/IC50
(U87-MG) (the concentration of VP-16 or doxorubicin at which
50% inhibition of MDM2-U87-MG cell viability can bemdm2 mediates tfie expression of mdrl and P-gp in glioma cells
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induced when treated for 72 h/that of U87-MG) was 5.0 and
4.5 respectively. These results show that the mdm2 gene
conferred resistance ofU87-MG cells to VP-16 or doxorubicin.
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Effect ofmdm2 on apoptosis induced by VP-16 and
doxorubicin
Recently, VP-16 and doxorubicin have been shown to induce
apoptosis in thymocytes (Onishi et al., 1993) or bone marrow
cells (Kondo et al., 1994). Therefore, we determined whether
MDM2-U87-MG cells also acquired resistance to apoptosis
induced by VP-16 and doxorubicin. As shown in Figure 3,
U87-MG cells treated with 5 jg ml-' VP-16 or 5 jMg ml-
doxorubicin for 72 h were found to contain fragmented DNA
in multiples of approximately 185 bp, giving rise to the
characteristic DNA 'ladder' pattern of apoptosis. In contrast,
DNA fragmentation in agarose gel was not detected in the
MDM2-U87-MG cells treated with these agents. Hoechst
33258 staining showed that the percentage of apoptotic cells
was increased in a dose-dependent manner when U87-MG
cells were treated with VP-16 or doxorubicin (Figure 4). As
expected, overexpression of MDM2 protein prevented the
induction of apoptotic cells by VP-16 or doxorubicin
(P<0.01 or P<0.01 respectively). Almost all apoptotic cells
also stained positive for DNA breaks (data not shown).
Effect ofmdm2 antisense on P-gp expression and VP-16/
doxorubicin-induced cytotoxicity in MDM2-U87-MG cells
As shown in Figure 5, MDM2-U87-MG cells treated with
mdm2antisenseshowedreduction inthelevelsofP-gp aswell as
MDM2protein 48 h after addingantisense. On the otherhand,
mdm2 sense did not cause any reduction in P-gp and MDM2
expression (data not shown). There was too much scatter in the
data from MTT growth inhibition assays with antisense for
statistically significant differences to be observed.
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U U87-MG treated with doxorubicin
0 MDM2-U87-MG treated with VP-16
+ MDM2-U87-MG treated with doxorubicin
0)
oD
ua E
_
b 2
4.- MDM2
0
._
a)
*- P-gp
Figure 1 Expression of mdrl and P-gp in U87-MG cells by
mdm2. (a) Expression of mdm2 and mdrl in U87-MG and
MDM2-U87-MG cells. Aliquots of 10 g RNA from each sample
were subjected to Northern blotting. The blot was reacted with a
mdm2- or mdrl-specific probe and rehybridised with a GAPDH-
specific probe to confirm adequate loading of all lanes. Lower
panel shows ethidium bromide staining. (b) Expression of MDM2
protein and P-gp in U87-MG and MDM2-U87-MG cell.
Immunoblotting using anti-MDM2 or P-gp MAb was performed
with equal amounts of proteins. The same experiment was
performed three times with similar results.
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Figure 2 Viability of both U87-MG and MDM2-U87-MG cells
treated with VP-16 or doxorubicin respectively. Tumour cells were
seeded at a density of 104 cells per well (0.1 ml) in 96-well flat-
bottomed plates and incubated at 37°C. Viability was determined
using a modified MTT assay 72h after adding drugs. Values
represent the mean+s.d. of results from three separate
experiments.
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Figure 3 DNA fragmentation assay in agarose gel. U87-MG
(lanes 2 and 4) and MDM2-U87-MG cells (lanes 3 and 5) were
treated with either 5Hgml-l VP-16 (lanes 2 and 3) or 5 gml-l
doxorubicin (lanes 4 and 5) for 72h respectively. Fragmented
DNA was isolated and electrophoresed in a 2.0% agarose gel
containing 0.5jugml- l ethidium bromide. Molecular weight
standards of multiples of 123bp DNA ladder (GIBCO BRL,
Tokyo) are shown in lane 1.
0.1
Drug concentration (ug ml-l)
Figure 4 Apoptotic cells by Hoechst 33258 staining. U87-MG
and MDM2-U87-MG cells were treated with VP-16 or
doxorubicin for 72h respectively. Five hundred cells stained
with Hoechst 33258 were counted, in randomly selected fields, for
each experiment and the percentage of apoptotic cells was
determined. Values represent the mean+s.d. of results from
three separate experiments.
Discussion
In this study, we present data showing that the mdm2 gene
induced the expression of the mdrl gene and P-gp in U87-
MG cells, and subsequently, conferred resistance to apoptotic
cell death induced by VP-16 and doxorubicin.
MDR is caused by overexpression of P-gp that binds
analogues of ATP (Schurr et al., 1989) and cytotoxic drugs
(Safa et al., 1986), exhibits ATPase activity (Sarkadi et al.,
1992), and serves as an ATP-conducting channel (Abraham
et al., 1993). P-gp appears to function as an energy-dependent
transport pump capable of effluxing cytotoxic agents and
thereby decreasing their intracellular concentration. Recent
studies have demonstrated that the expression of P-gp may
not only predict the response of individual tumours to
specific cytotoxic agents but may also provide important
criteria for determining successful chemotherapeutic proto-
cols (Chabner and Wilson, 1991; Goldstein and Ozols, 1991).
Consequently, to evaluate the mechanisms regulating the
expression of mdrl and P-gp has obvious clinical implica-
tions.
Chin et al. (1992) have recently indicated that the mdrl
gene could be activated during tumour progression associated
with mutations in p53 and ras. In addition, Zastawny et al.
(1993) demonstrated that the wild-type p53 protein repressed
P-gp-promoter activity, while mutant p53 enhanced it.
Certainly, p53 mutations appear to be the most common
genetic alterations in human tumours including malignant
gliomas (Hollstein et al., 1991; Levine et al., 1991; Sidransky
et al., 1992; Vogelstein and Kinzler, 1992; Finlay, 1993;
Harris and Hollstein, 1993). However, if mutational
inactivation of p53 could be correlated with the occurrence
of the MDR phenotype during tumour progression, other
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Figure 5 Effect of mdm2 antisense on MDM2 and P-gp
expression in MDM2-U87-MG cells. Expression of MDM2
protein and P-gp in MDM2-U87-MG cells treated with mdm2
antisense. mdm2 antisense was added to tumour cells every 24h.
Tumour cells treated with mdm2 antisense for 2 days were lysed.
Immunoblotting using anti-MDM2 or P-gp MAb was performed
with equal amounts of proteins. The same experiment was
performed three times with similar results.
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factors modulating the function of wild-type p53 protein
could also influence the resistance of tumour cells to
chemotherapy. These factors include MDM2 (Oliner et al.,
1992; Momand et al., 1992), the human papilloma virus E6
proteins (Scheffner et al., 1990; Crook et al., 1992), or the
adenovirus El1 gene (Lowe et al., 1993). In particular, mdm2
has recently been shown to induce p53 inactivation in a
significant percentage of sarcomas and malignant gliomas
without p53 mutations (Oliner et al.. 1993; Reifenberger et
*al.. 1993).
The mdm2 gene was initially identified and cloned on the
basis of its amplification in a highly tumorigenic derivative of
NIH-3T3 cells containing double minutes and has subse-
quently been shown to confer tumorigenic properties upon
transfected cell (Cahilly-Snyder et al.. 1987; Fakharzadeh et
al., 1991; Oliner et al.. 1992). Recently, several studies have
indicated that MDM2 can form complexes with both wild-
type and mutant p53 proteins (Momand et al., 1992; Olson et
al.. 1993), and inhibit p53 function by concealing the
activation domain of p53 from the cellular transcription
machinery (Oliner et al. 1993). Taken together. we suggest
that mdm2, besides possessing oncogenic activity (Fakharza-
deh et al., 1991; Olson et al., 1993), may have a further
deleterious effect by providing the mechanism by which the
mdrl gene and P-gp can be overexpressed in human tumours.
Further experiments. however, are needed to determine
whether increased mdm2 and P-gp expression are stable or
transient phenomenona in the transfectant sublines. More
recently, we demonstrated that MDM2 protein conferred
resistance of human glioblastoma cells to non-P-gp drug.
cisplatin-induced apoptosis (Kondo et al., 1995). Therefore.
our data do not allow assessment of the extent to which
resistance in the transfectants was due to expression of
MDM2 or P-gp. To discern between the two mechanisms.
data would be needed on (1) cellular pharmacology of VP-16
and doxorubicin; or (2) the effects of anti-P-gp oligonucleo-
tide treatment on resistance levels. Taken together. MDM2
may prevent chemotherapy-induced apoptosis. and subse-
quently., the suppression of MDM2 expression may become a
novel approach for the successful treatment of tumours.
Abbreviations
MDR, multidrug resistance: P-gp. P-glycoprotein: mdm2. murine
double minute 2: MDM2-U87-MG cells. MDM2-expressing U87-
MG cells: VP-16. etoposide; DMEM. Dulbecco's modified Eagle
medium: FCS. fetal calf serum. MAb. monoclonal antibody:
PMSF, phenylmethylsulphonyl fluoride: Hoechst 33258. DNA-
binding fluorochrome bis (benzimide) trihydrochloride.
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